)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Addex Therapeutics (ADXN) investor relations material
Addex Therapeutics H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary1 Oct, 2025
Executive summary
Significant progress in GABA B PAM program with IND enabling studies completed for substance use disorders in partnership with Indivior; company eligible for milestone payments and royalties.
Regained rights to mGluR2 positive allosteric modulator program from Johnson & Johnson and evaluating new indications.
Repositioned diproglurant (mGluR5 negative modulator) for brain injury recovery, secured option for exclusive IP license, and announced collaboration with Sinntaxis AB in April 2025.
Invested in Stellicla, a company with a precision medicine platform for neurodevelopmental disorders, supporting broader application in heterogeneous patient populations.
Divested allosteric modulator discovery platform and preclinical programs to Neurosterix Pharma Sàrl in April 2024, receiving CHF 5.0 million and a 20% equity interest in Neurosterix US Holdings LLC.
Financial highlights
Ended H1 2025 with CHF 2.3 million in cash, providing runway through mid-2026.
Net loss for H1 2025 was CHF 3.3 million, compared to a net profit of CHF 9.8 million in H1 2024, which included a one-time gain from the Neurosterix Transaction.
Revenue for H1 2025 was CHF 0.35 million, down from CHF 0.65 million in the prior year, due to completion of the Indivior research phase.
R&D expenses for Q2 2025 were $200,000, down $100,000 year-over-year, mainly due to the end of the Indivior research phase.
Share of net loss from Neurosterix was CHF 2.1 million for H1 2025.
Outlook and guidance
Cash position does not fund unpartnered programs into the clinic; additional financing required.
IND enabling studies for independent GABA B PAM program for chronic cough ready to start, pending financing.
Expenses expected to increase as GABA B PAM for chronic cough advances and further clinical trials are initiated.
Management continues to seek additional funding through equity, collaborations, or licensing.
Stellicla pursuing Series C financing and exploring public listing options.
Assess going concern beyond mid-June 2026.
Impact of Janssen termination on pipeline strategy?
Future of Neurosterix zero-cost services?
Funding unpartnered programs?
Next steps for mGlu2 program (ADX71149)?
GABAB PAM cough program's patient target?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Addex Therapeutics earnings date
Q3 202510 Nov, 2025
Next Addex Therapeutics earnings date
Q3 202510 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Addex Therapeutics Ltd is a biotechnology company focused on the discovery and development of small molecule therapies for neurological disorders. The company specializes in allosteric modulators, a drug discovery approach aimed at targeting specific receptors in the central nervous system to treat conditions such as Parkinson’s disease, epilepsy, and schizophrenia. Addex conducts clinical and preclinical research to advance its pipeline of investigational treatments. The company is headquartered in Geneva, Switzerland, and its shares are listed on the SIX Swiss Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage